ContributorsPublishersAdvertisers

Clinical Management of ALK+ Advanced NSCLC

onclive.com
 2021-10-18

Cover picture for the articleBenjamin Levy, MD: There are multiple standard-of-care therapies for patients with advanced ALK-rearranged lung cancer. Crizotinib, the first, was developed as a MET inhibitor initially, but it had activity in ALK-rearranged lung cancer. When you compared crizotinib to chemotherapy, there was an improvement in progression-free survival [PFS] and intracranial-response rates for...

www.onclive.com

Comments / 0

Comments / 0